# OnCo record paper-majestec-1-teclistamab-nejm-2022 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-majestec-1-teclistamab-nejm-2022/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-majestec-1-teclistamab-nejm-2022" ;
  schema:name "MajesTEC-1: teclistamab, an off-the-shelf BCMA bispecific antibody, in heavily pretreated myeloma"@en ;
  schema:description "A ready-made antibody that pulls T cells onto myeloma cells produced responses in 63% of patients after a median of five prior therapies, without the wait for cell manufacturing."@en ;
  schema:url <https://onco.cc/key-papers/paper-majestec-1-teclistamab-nejm-2022/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2203478>, <https://clinicaltrials.gov/study/NCT04557098> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa2203478> ;
  schema:datePublished "2022"^^xsd:gYear ;
  schema:author "Moreau P, Garfall AL, van de Donk NWCJ, et al." ;
  onco:related <https://onco.cc/pairings/bispecific-infection-prophylaxis/>, <https://onco.cc/pairings/bcma-then-gprc5d/>, <https://onco.cc/key-papers/paper-magnetismm-3-elranatamab-natmed-2023/> ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/> ;
  onco:technologies <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/t-cell-engager/> ;
  onco:targets <https://onco.cc/targets/bcma/>, <https://onco.cc/targets/cd3/> ;
  onco:drugs <https://onco.cc/drugs/teclistamab/>, <https://onco.cc/drugs/talquetamab/>, <https://onco.cc/drugs/elranatamab/> ;
  onco:companies <https://onco.cc/companies/johnson-johnson/> ;
  onco:terms <https://onco.cc/terms/crs/>, <https://onco.cc/terms/orr/> ;
  onco:trials <https://onco.cc/trials/majestec-1/>, <https://onco.cc/trials/majestec-3/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-toxicity-qol/>, <https://onco.cc/bottlenecks/b-dose-optimisation/> ;
  onco:journals <https://onco.cc/journals/nejm/> .